

**Detection of 14q32 Rearrangements In Patients
With Multiple Myeloma, Using Simultaneous
FISH Analysis Combined With
Immunofluorescence, Using CD138**

Thesis

Submitted for Partial Fulfillment of M.Sc. Degree in
Clinical and Chemical Pathology

By

Laila Mahmoud Hafez Al-Naka

M.B., B.Ch.

Faculty of Medicine - Ain Shams University

Supervised by

Professor / Hala Mahmoud Hamdi Abaza

Professor of Clinical Hematology,

Faculty of Medicine - Ain Shams University

Doctor / Soha Raouf Youssef

Assistant Professor of Clinical and Chemical Pathology,

Faculty of Medicine - Ain Shams University

Doctor / Abeer Attia Saad El-Deen

Lecturer of Clinical and Chemical Pathology,

Faculty of Medicine - Ain Shams University

**Faculty of Medicine,
Ain-Shams University**

2010

اكتشاف مُراتَبات
14q32 في مرضى الورم النقوي المتعدد باستخدام تحليل
التهجين التآلقي في الموضع (FISH) المتواقت مع التآلق
المناعي باستخدام CD138

رسالة

مقدمة توطئة للحصول على درجة الماجستير في
الباثولوجيا الإكلينيكية و الكيمائية

مقدمة من

الطبيبة ليلي محمود حافظ الناقة
بكالوريوس الطب و الجراحة
كلية الطب - جامعة عين شمس

تحت اشراف

الأستاذ الدكتور / هالة محمود حمدي أباطة
أستاذ أمراض الدم الإكلينيكية
كلية الطب - جامعة عين شمس

الدكتور / سها رؤوف يوسف
أستاذ مساعد الباثولوجيا الإكلينيكية و الكيمائية
كلية الطب - جامعة عين شمس

الدكتور / عبير عطية سعد الدين
مدرس الباثولوجيا الإكلينيكية و الكيمائية
كلية الطب - جامعة عين شمس

كلية الطب
جامعة عين شمس

2010

To My parents,

*To my beloved, caring and
understanding husband.*

Acknowledgement

First of all, Thanks to **Allah**

I would like to express my deepest thanks, gratitude and profound respect to my honored professor, **Prof. Dr. Hala Mahmoud Hamdi Abaza**, Professor of Clinical Hematology, Faculty of Medicine, Ain-Shams University, for her meticulous supervision. I consider myself fortunate to work under her supervision. Her constant encouragement and constructive guidance were of paramount importance for the initiation, progress and completion of this work.

I would like to extend my thanks to **Dr. Soha Raouf Youssef**, Assistant Professor of Clinical and Chemical Pathology, Faculty of Medicine, Ain-Shams University, for her active participation in this work. She really did her best to get this work fulfilled.

My special thanks to **Dr. Abeer Atia Saad El-Deen**, Lecturer of Clinical and Chemical Pathology, Faculty of Medicine, Ain-Shams University, who offered me a lot of guidance, continuous encouragement and advice while supervision every step in this work.

Also I would like to thank **cytogenetics laboratory** as well as **immunology laboratory** members for their help and support. Also I would like to thank **Dr. Gehan Mohamad Kamal**, Lecturer of Clinical Hematology, Ain-Shams University, for her assistance in data collection.

Laila Annaka

TABLE OF CONTENTS

List of Abbreviations	I
List of Figures.....	IV
List of Tables	VI
Introduction	1
Aim of the work.....	3
Review of Literature.....	4
<u>Chapter I: Multiple myeloma</u>	
▪ Definition	4
▪ Epidemiology and incidence	5
▪ Normal plasma cell development	5
▪ Pathogenesis	7
▪ Etiologic Factors	15
▪ Clinical Manifestations	16
▪ Standard laboratory and imaging modalities	21
▪ Diagnostic Criteria	31
▪ Staging	34
▪ Prognostic Factors	36
▪ Treatment of MM	39
<u>Chapter II: Cytogenetics of Multiple Myeloma</u>	
▪ Aneuploidy	45
▪ Chromosome 13 abnormalities	47
▪ IgH switch translocations	48
▪ Chromosome 17 deletions	52



- Chromosome 22 abnormalities53
- Chromosome 1 abnormalities54

Chapter III: FICTION Technique

- Introduction55
- Components of FICTION technique56
- Applications of FICTION technique66

Subjects and Methods 69

Results 77

Discussion 99

Summary & Conclusion 110

Recommendations 114

References 115

Tables of Raw Data 143

Arabic Summary



LIST OF ABBREVIATIONS

AL	Amyloid light chain
ASCT	Autologous stem-cell transplantation
BACs	Bacterial artificial chromosomes
bFGF	Basic fibroblast growth factor
BJP	Bence Jones protein
β₂M	β ₂ microglobulin
BMSCs	Bone marrow stem cells
CCND1	Cyclin D1
CD	Cluster of differentiation
cDNA	Complementary DNA
CLL	Chronic lymphoid leukemia
c-MAF	Musculoaponeurotic fibrosarcoma oncogene
c-Myc	Cellular myelocytomatosis
CNS	Central nervous system
CR	Complete response
CRP	C-reactive protein
CT	Computered tomography
DAPI	4',6-diamidino-2-phenylindole
Dkk-1	Dickkopf-related protein-1
DNA	Deoxy ribose nucleic acid
EBMT	European Group for Blood and Marrow Transplant
EFS	Event-free survival
ERK	Extracellular signal-regulated kinase
Fas L	Fas ligand
Fc	Fragment crystalliable
FCM	Flow cytometry
FICTION	Fluorescence immunophenotyping and interphase cytogenetics as a tool for the investigation of neoplasm
FISH	Fluorescence in situ hybridization
FLC	Free light chain assay
HDT	High dose therapy
HGF	Hepatocyte growth factor
HIV	Human immunodeficiency virus
HRS	Hodgkin/Reed–Sternberg cells

HS	Highly significant
IAPs	Inhibitor of apoptosis proteins
IF	Immunofluorescence
IDB	International Data Base
IFX	Immunofixation
Ig	Immunoglobulin
IgH or IGH	Immunoglobulin Heavy Chain
IGF1	Insulin-like growth factor 1
IL-1β	Interleukin-1 β
IL3	Interleukin 3
IL6	Interleukin 6
IMWG	International Myeloma Working Group
IP	Immunophenotyping
IRF	Interferon responsive factor
ISS	International Staging System
JAK2	Janus kinase 2
Kb	Kilobase
LDH	Lactate dehydrogenase
LSI	Locus specific identifier
M	Monoclonal
MCL1	Myeloid cell leukaemia sequence 1
M-FICTION ..	Multicolor FICTION
MGUS	Monoclonal gammopathy of undetermined significance
MIP-α	Macrophage inflammatory protein- α
MM	Multiple myeloma
MMSET	Multiple myeloma SET
MPR	Melphalan, prednisone and lenalidomide
MPT	Melphalan, prednisone and thalidomide
MPV	Melphalan, prednisone and bortezomib
MRD	Minimal residual disease
MRI	Magnetic resonance imaging
MYEOV	Myeloma over-expressed gene
NFκB	Nuclear factor κ B
NS	Non-significant
OPG	Osteoprotegerin
OS	Overall survival
P	Short arm of chromosome
PB	Peripheral blood
PBS	Phosphate buffered saline
PBSCT	Peripheral blood stem cell transplantation

PC5	R Phycoerythrin Cyanin 5.1
PCD	Plasma cell dyscrasia
PCL	Plasma cell leukemia
PCLI	Plasma cell labeling index
PD	Progressive disease
PI3K	Phosphatidyl -Inositol 3-kinase
Plasma cells	PCs
PLT	Platelet
POEMS	Polyneuropathy, Organomegaly, Endocrinopathy/ Edema, M-protein and Skin abnormalities
PR	Partial response
Q	Long arm of chromosome
RANKL	Receptor activator of NFκB
Rel	Reticolo-endotheliosis oncogene
Rev/Dex	Lenalidomide- dexamethasone
RTN4R	Reticulon 4 receptor
Runx2	Runt-related transcription factor 2
S	Significant
SCF	Stem cell factor
Scr	Stringent complete response
SD	Stable disease
SDF-1 α	Stromal derived factor-1 α
Sig	Significance
SMM	Smoldering multiple myeloma
SPEP	Serum protein electrophoresis
STAT3	Signal transducer and activator of transcription 3
TBX1	T-box1
TGF- β	Transforming growth factor-β
Thal/Dex	Thalidomide/dexamethasone
TNF	Tumor necrosis factor
UPEP	Urine protein electrophoresis
VAD	Vincristine, doxorubicin and dexamethasone
VCAM-1	Vascular cell adhesion molecule-1
VDJ	Variable Diversity Joining regions
VEGF	Vascular endothelial growth factor
VGPR	Very good partial response
WHO	World health organization
YACs	Yeast artificial chromosomes

List of Tables

Table. No.	Title	Page No.
1.	Evaluation of a patient with MM.....	31
2.	Clinical and laboratory abnormalities in MM	31
3.	Diagnostic criteria for plasma cell disorders.....	32
4.	The Durie-Salmon staging system	35
5.	The International Staging System (ISS).....	35
6.	Selected poor prognostic factors in MM	38
7.	International Myeloma Working Group uniform response criteria for MM	40
8.	Comparison of morphological to IF assessment of BM PCs	86
9.	Comparison between group A and group B, as regards clinical and demographic data	86
10.	Comparison between group A and group B, as regards laboratory data	87
11.	Comparison of positive to negative cases for 14q32 rearrang -ement by FICTION, as regards percent BM PCs	87
12.	Comparison of OS of patients, as regards clinical and demographic data (Log rank test).	88
13.	Comparison of OS of patients, as regards laboratory data (Log rank test)	89
14.	Diagnostic Validity Test	90
15.	Comparison between FICTION and FISH techniques, as regards the detection of 14q32 rearrangement.....	90

List of Figures

Fig. No.	Title	Page No.
1.	The development of normal plasma cells	6
2.	Pathogenesis of MM	7
3.	Factors implicated in myeloma bone disease	11
4.	Peripheral blood from patient with MM	22
5.	Serum protein electrophoresis in patient with MM	24
6.	Immunofixation (serum and urine) in patient with MM	26
7.	BM examination of patient with MM	28
8.	A lateral skull X-ray with typical findings of MM	30
9.	Chromosome 13	47
10.	t(4;14)(p16.3;q32) in MM	48
11.	Scheme of the principle of the FISH experiment to localize a gene in the nucleus	58
12.	FISH using whole-chromosome painting probes	60
13.	Dual fusion and break apart probes	62
14.	IF staining of plasma cells using anti-CD138 PE conjugated antibody	65
15.	Paraffin section FISH analysis with CD138-IF	66
16.	Multicolor interphase cytogenetics for the detection of IgH translocations and 13q deletion in PCD	68
17.	Frequency of 14q32 rearrangement in MM by FICTION	80
18.	Frequency of 14q32 rearrangement in MM by FISH	80

Fig. No.	Title	Page No.
19.	Correlation between FICTION, percent BM PCs by morphology and by IF staining.....	90
20.	Comparison of OS for serum albumin level and CRP	91
21.	Kaplan Meier OS curve for the age.....	91
22.	Kaplan Meier OS curve for the sex	92
23.	Kaplan Meier OS curve for the 14q32 rearrangements	92
24.	Kaplan Meier OS curve for the stage	93
25.	Kaplan Meier OS curve for the Hb levels	93
26.	Kaplan Meier OS curve for the platelet count.....	94
27.	Kaplan Meier OS curve for the total protein levels.....	94
28.	Kaplan Meier OS curve for the serum albumin levels.....	95
29.	Kaplan Meier OS curve for the residual γ globulins	95
30.	Kaplan Meier OS curve for the serum creatinine	96
31.	Kaplan Meier OS curve for the serum CRP.....	96
32.	Kaplan Meier OS curve for the serum IFX	97
33.	Positive FICTION technique	98
34.	Negative FICTION technique	98

Diagrams

1.	The stage and the outcome of the studied MM patients	78
----	--	----

INTRODUCTION

Multiple myeloma (MM) is an incurable, but treatable, hematological disorder characterized by accumulation of malignant plasma cells within the bone marrow (BM) (**Chen et al., 2007**). Myeloma cells can induce alterations in the marrow microenvironment, which, in turn provides survival factors (IL-6, IL-15, insulin-like growth factor-1, and hepatocyte growth factor) that contribute to the resistance of myeloma cells to many anticancer drugs (**Barlogie et al., 2006**).

The MM is characterized by a clinical pentad: (a) anemia, (b) a monoclonal protein in the serum or urine or both, (c) abnormal bone radiographs and bone pain, (d) hypercalcemia, and (e) renal insufficiency or failure. Mortality rates are consistently higher among men than women in each age group (**Dispenzieri et al., 2009**).

It has been reported that, all MM patients harbor cytogenetic abnormalities sometime during the course of the disease. Frequent chromosome abnormalities in MM include 14q32 rearrangements, 13q deletion/monosomy 13, 1q duplication, 1p, 6p, 11q and 17p deletions (**Yuregir et al., 2009**).

Chromosomal 14q32 region containing the immunoglobulin heavy chain (IgH) locus has been identified as a recurrent hotspot of translocations in myeloma, with a frequency of up to 75% (**Dispenzieri et al., 2009**). They are associated with translocations involving the IgH locus at chromosome 14q32, and one of several partner genes including

CCND1 (11q13), MMSET (4p16), CCND3 (6p21), CMAF(16q32) and MAFB (20q11) (**Smadja et al., 2003**). The IgH translocations correlate with poor prognosis in multiple myeloma (**Terpos et al., 2006**).

Identification of the recurring translocations in routine evaluation of plasma cell myeloma, therefore, provides important information that may assist in the diagnostic and prognostic assessment of such cases (**Cook et al., 2006**). Although cytogenetics is becoming a major parameter in MM, it is hampered by hypoproliferative nature of plasma cells and partial infiltrates (**Avet-Loiseau, 2007**).

The fluorescence in-situ hybridization (FISH) is probably the best method for cytogenetic assessment in MM, but it requires the identification of the malignant cells (**Avet-Loiseau, 2007**). The FISH analysis combined with simultaneous immunofluorescence (IF) using CD138 is an attractive alternative approach for evaluation of chromosomal changes in MM (**Cook et al., 2006**).

The FISH can be performed on dewaxed tissue sections, but this technique remains potentially challenging; the scoring of individual nuclei is difficult due to cellular overlap and nuclear truncation. Moreover, fixation and embedding procedures may produce artifacts in tissue, thereby interfering with DNA hybridization. Alternatively, Buno and his coworkers clearly showed that FISH using tissue imprints, cytopreps, and BM smears is an easy, rapid, and reliable method to detect abnormalities with high sensitivity and specificity (**Buno et al., 2005**).

Aim of the Work

- To detect rearrangements of IgH locus on chromosome 14q32, using FISH analysis combined with simultaneous IF using CD138, on archival BM slides.
- To study the frequency of these rearrangements in MM patients.
- To correlate the prognostic value of these rearrangements with other known prognostic factors.